Global pharma powerhouse Bristol Myers Squibb is doubling down on its blockbuster heart therapy, unveiling a wave of new clinical and real-world evidence that could cement Camzyos as a transformative treatment for patients with obstructive hypertrophic cardiomyopathy (oHCM).

 

At the center of its recent announcement is the first-ever Phase 3 trial of a cardiac myosin inhibitor in younger patients. Full results from the SCOUT-HCM study show Camzyos met its primary endpoint and multiple secondary goals, signaling potential for adolescents with symptomatic oHCM—a group with few treatment options beyond symptom control.

 

“Camzyos has redefined the standard of care for oHCM treatment in adults, which is further supported by the long-term and real-world data being presented during the meeting,” said Cristian Massacesi, executive vice president, Chief Medical Officer and Head of Development, Bristol Myers Squibb. 

 

“We also look forward to presenting data from the SCOUT-HCM study that supports the potential of Camzyos in adolescents with oHCM, a patient population whose current treatment options are limited to symptom management.”

 

The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials.

 

Findings from the DISCOVER-HCM study, a large real-world analysis across the U.S. and Puerto Rico, show safety and effectiveness results consistent with earlier clinical trials. Additional real-world data from MARVEL-HCM highlight sustained benefits in routine care, while emphasizing the importance of accurately diagnosing obstructive forms of the disease to guide treatment.

 

Meanwhile, results from the COMPASS-HCM study point to rapid patient benefits, with improvements in quality of life and health status reported as early as two weeks after starting treatment.

 

Together, the data package positions Camzyos not just as an effective therapy, but as a potential cornerstone treatment across a broader spectrum of oHCM patients—signalling a shift in how the disease may be managed in both adults and younger populations.